DR-093 Whole genome Sequencing to estimate TEmozolomide Associated Response IN Gliomas (STEARING)

“Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Since 2005, standard treatment consists of surgery followed by radiation therapy with concurrent and adjuvant temozolomide chemotherapy, taking ± 8.5 months in total. Despite optimal treatment, GBM outcome is almost inevitably fatal, usually within 16 months after diagnosis. There is an urgent need to improve treatment of patients with GBM, both by selection of patients most likely to respond to standard therapy, as well as through the identification of novel targets for [combination] treatment.

DR-093 is an extension of DR-060 and DR-076”

Filip de Vos University Medical Center Utrecht the Netherlands